產(chǎn)品目錄

規(guī)格	10mg 50mg
CAS	495076-64-7
別名
化學(xué)名	(Z)-4-(benzyloxy)-N-((1-(dimethylamino)cyclopentyl)methyl)-3,5-dimethoxybenzimidic acid hydrochloride
分子式	C24H32lN2O4.HCl
分子量	448.98
溶解度	<8.98mg/ml in H2O; <44.9mg/ml in DMSO
儲(chǔ)存條件	Desiccate at RT
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request

產(chǎn)品描述：

IC50:16 nM

Org 25543 hydrochloride is a potent and selective glycine transporter type 2 (GlyT2) inhibitor for hGlyT2. Two major subtypes of glycine transporter are type 1 (GlyT-1) and type 2 (GlyT-2) revealed by molecular cloning. The GlyT-2 transporter has a similar distribution to ssGlyR with being confined to the spinal cord and brain stem, whereas the GlyT-1 transporter has a wide distribution throughout the CNS.

In vitro: Org 25543 was identified as the most active compound in the library. Org 25543 has both cyclopentyl and BnO groups. As indicated by its favorable physicochemical parameters, Org 25543 exhibits a well penetration of bloodbrain barrier (logBB 0.6). Since Org 25543 also exhibits good metabolic stability (80% remaining after 30 min) in plasma and mouse hepatic microsomes, the compound should prove to be a valuable agent that might help to establish pharmacology of the GlyT-2 transporter [1].

In vivo: The administration of the antiallodynia effect of GlyT2 inhibitors ORG25543 and ALX1393 appeared without a time lag. The dose-dependent antiallodynia effect displayed by ORG25543 was effective in a limited-dose range. In glycinergic nerve terminals, dysfunction of GlyT2 function plays a very key role in insufficient transmitter loading of synaptic vesicles. However, no sign of hyperekplexia appeared by the administration of GlyT2 inhibitors. Pharmacological manipulation attenuated Glycine refilling in glycinergic nerve terminals in vivo, when reproduction of the antiallodynia effect by repeated treatment of ORG25543 (i.v.) with similar potency per time. [2].

Clinical trial: So far, no clinical study has been conducted

特別提醒：

1. 本產(chǎn)品僅供科研使用。請(qǐng)勿用于醫(yī)藥、臨床診斷或治療，食品及化妝品等用途。請(qǐng)勿存放于普通住宅區(qū)。

2. 為了您的安全和健康，請(qǐng)穿好實(shí)驗(yàn)服并佩戴一次性手套和口罩操作。

原創(chuàng)作者：上海莼試生物技術(shù)有限公司

在線咨詢

留言注意事項(xiàng)：

1.遵守中華人民共和國(guó)有關(guān)法律、法規(guī)，尊重網(wǎng)上道德，承擔(dān)一切因您的行為而直接或間接引起的法律責(zé)任。

2.請(qǐng)您真實(shí)的反映產(chǎn)品的情況,不要捏造、誣蔑、造謠。如對(duì)產(chǎn)品有任何疑問,也可以留言咨詢。

3.未經(jīng)本站同意，任何人不得利用本留言簿發(fā)布個(gè)人或團(tuán)體的具有廣告性質(zhì)的信息或類似言論。

您感興趣的產(chǎn)品*
您的單位*
聯(lián)系人*
聯(lián)系電話*
詳細(xì)地址*
常用郵箱*
請(qǐng)輸入您對(duì)我們的意見或建議*
驗(yàn)證碼*